Skip to content

Bausch + Lomb Corp.

US · BLCO #1909 by market cap Listed 2022
19.38 -1.31 -6.33%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions increased by 5 in the most recent period (2026/Q3).
  • Total institutional ownership fell 1.9 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
97.59% -1.86pp
Institutions
116 +5
As of
2026/Q3 vs. prior period

Holder types

Public Company88.25%
Hedge Fund4.82%
Mutual Fund1.93%
Family Office/Trust1.23%
VC/PE Fund1.12%
Private Company0.23%
Individual/Insider0.18%
Other2.23%

Top holders as of 2025-12-09

Bausch Health Companies Inc. 86.84% · 310.45M sh
Icahn Capital LP 0.98% · 3.50M sh
Brookfield Corporation 0.96% · 3.44M sh
Deutsche Bank Aktiengesellschaft 0.93% · 3.33M sh
D. E. Shaw & Co., L.P. 0.93% · 3.32M sh
Davidson Kempner Capital Management LP 0.88% · 3.16M sh
GoldenTree Asset Management LP 0.74% · 2.66M sh
T. Rowe Price Group, Inc. 0.60% · 2.16M sh
Glenview Capital Management, LLC 0.54% · 1.92M sh
Arrowstreet Capital, Limited Partnership 0.38% · 1.36M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 31 buys · 18 sells

NameRoleStake
Bausch Health Companies Inc. -- 86.84%
Brenton Saunders Chairperson & CEO 0.12%
Osama Eldessouky Chief Financial Officer 0.06%
A. Robert Bailey Chief Legal Officer 0.04%
Yehia Hashad Executive VP of Research & Development and Chief Medical officer 0.03%
Andrew von Eschenbach Former Independent Director 0.01%
Luc Bonnefoy President of Surgical 0.01%
Richard De Schutter Former Independent Director 0.01%
Andrew Stewart President of Global Pharmaceuticals & International Consumer 0.01%
Thomas Appio Interim CEO & Chairman of the Board 0.01%
John Paulson Independent Director 0.01%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-11 Karen Ling Former Independent Director Intent to Sell (Form 144) -12,838 $21.01
2026-11-02 Nathalie Bernier Former Independent Director Intent to Sell (Form 144) -40,022 $19.88
2026-10-28 John Paulson Independent Director Other Acquisition +1,125 $20.40
2026-10-28 Russel Robertson Independent Director Other Acquisition +1,256 $20.40
2026-10-28 Eduardo Alfonso Independent Director Other Acquisition +1,125 $20.40
2026-10-28 Frederick Munsch Chief Accounting Officer Derivative Exercise and Sale -112,015 $17.96–20.48
2026-09-27 Karen Ling Former Independent Director Intent to Sell (Form 144) -4,500 $16.83
2026-08-11 Laurence Paul Lead Independent Director Other Acquisition +11,776 --
2026-08-11 Robert Chersi Director Other Acquisition +11,776 --
2026-08-11 Barbara Trebbi Director Other Acquisition +11,776 --
2026-08-09 Frederick Munsch Chief Accounting Officer Open Market Disposition -52,900 $16.78
2026-08-09 Frederick Munsch Chief Accounting Officer Intent to Sell (Form 144) -52,900 $16.78
2026-08-06 Andrew von Eschenbach Former Independent Director Open Market Disposition -18,559 $16.50–16.58
2026-08-06 Andrew von Eschenbach Former Independent Director Intent to Sell (Form 144) -6,059 $16.58
2026-08-05 Andrew von Eschenbach Former Independent Director Intent to Sell (Form 144) -12,500 $16.50
2026-08-04 Brenton Saunders Former Chief Executive Officer Sale to Issuer -4,231 $16.76
2026-08-04 Brenton Saunders Former Chief Executive Officer Other Acquisition +281,879 --
2026-08-04 Thomas Appio Interim CEO & Chairman of the Board Initial Statement of Beneficial 0 --
2026-08-04 A. Robert Bailey Chief Legal Officer Other Acquisition +33,557 --
2026-08-04 Osama Eldessouky Chief Financial Officer Other Acquisition +50,335 --

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Bausch + Lomb Corp. discussion 0 comments

Add a comment